芪蛭益肺颗粒对COPD大鼠模型SP-A表达和超微结构的影响被引量：8

下载PDF

导出

摘要目的探讨芪蛭益肺颗粒对慢性阻塞性肺疾病(COPD)大鼠模型肺表面活性物质相关蛋白A(SP-A)表达及肺组织超微结构的影响。方法运用气管内滴注脂多糖加烟熏28d法建立COPD大鼠模型,免疫组化法检测SP-A表达及透射电镜观察肺泡Ⅱ型上皮细胞超微结构变化。结果与空白组比较,模型组大鼠SP-A表达明显减少,有显著差异(P<0.01),肺泡Ⅱ型上皮细胞超微结构不完整;与模型组比较,芪蛭益肺颗粒治疗组大鼠SP-A表达明显增强,差异显著(P<0.01),肺泡Ⅱ型上皮细胞超微结构完整。结论芪蛭益肺颗粒可显著提高模型大鼠SP-A表达,改善细胞超微结构,对COPD的发生起到预防保护作用。

作者李金田张莉刘永琦李娟张毅魏舒畅

机构地区甘肃中医学院

出处《中国老年学杂志》 CAS CSCD 北大核心 2010年第5期633-635,共3页 Chinese Journal of Gerontology

基金甘肃省科计攻关项目(2GS035-A43-067) 甘肃省教育厅导师项目(0505-02)

关键词芪蛭益肺颗粒 COPD SP-A 超微结构

分类号 R256.14 [医药卫生—中医内科学]

引文网络
相关文献

参考文献9

1石喜亮.慢性阻塞性肺疾病的中医辨治要点[J].现代中医药,2006,26(3):46-47. 被引量：6
2Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease ( GOLD ) Workshop summary[J]. Am J Respir Crit Care Med, 2001 ;163(5) :1256-76.
3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量：8233
4宋一平,崔德健,茅培英,王德文.慢性阻塞性肺疾病大鼠模型的建立及药物干预的影响[J].中华内科杂志,2000,39(8):556-557. 被引量：255
5Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease[ J]. Lancet,2004;364(9438) :985-96.
6Barnes PJ. ABC of chronic obstructive pulmonary disease: Future treat- ments[ J]. BMJ,2006 ;333 ( 7561 ) :246-8.
7Friedrich B, Schmidt R, Reiss I,et al. Changes in biochemical and biophysical surfactant properties with cardiopulmonary byhass in children [J]. Crit Care Med,2003 ;31 ( 1 ) :284-90.
8金婧.肺表面活性物质相关蛋白与临床肺疾病[J].国外医学（儿科学分册）,2003,30(3):130-132. 被引量：10
9王方勇,陈政良.SP-A、SP-D与肺部天然免疫防御[J].免疫学杂志,2002,18(B06):75-77. 被引量：8

二级参考文献32

1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量：279
2Hertin E, Moiler O, Schiffmann JH, et al. Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome[J]. Acta Paediatr, 2002,91(11):1174-8.
3Gunther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema[J]. Am J Respir Crit Care Med, 1996,153(1):176-84.
4Huffman JA, Hull WM, Dranoff G, et al. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deffident mice[J]. J Clin Invest, 1996,97(3):649-55.
5McCormack FX, King TE, Bucher BL, et al. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 1995,152(2):751-9.
6Honda Y, Kuroki Y, Shijubo N, et al. Aberrant appearance of lung surfactant protein A in sere of patients with idiopathic pulmonary fibrosis and its clinical significance[J]. Respiration, 1995,62(2):64-9.
7Takahashi H, Honda Y, Kuroki Y, et al. Pulmonary surfactant protein A: a serum marker of pulmonary fibrosis in patients with collagen vascular diseases[J]. Clin Chim Acta, 1995,239(2):213-5.
8Honda Y, Kuroki Y, Matsuura E, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids[J]. Am J Respir Crit Chre Med, 1995,152(6 Pt 1):1860-6.
9Thomas AQ, Lane K, Phillips J 3rd, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred[J]. Am J Respir Crit Care Med, 2ff)2,165(9):1322-8.
10Seifart C, Seifart U, Plagens A, et al. Surfactant protein B gene variations enhance susceptibility to squamous cell carcinoma of the lung in German patients[J]. Br J Cancer, 2002,87(2):212-7.